AIDX
Income statement / Annual
Last year (2025), 20/20 Biolabs Inc's total revenue was $2.05 B,
an increase of 116,608.49% from the previous year.
In 2025, 20/20 Biolabs Inc's net income was -$3.74 B.
See 20/20 Biolabs Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$2.05 B |
$1.75 M |
$1.42 M |
$11.06 M |
$9.62 M |
$2.33 M |
$288.30 K |
$277.05 K |
$313.21 K |
$427.00 K |
| Cost of Revenue |
$1.44 B
|
$1.39 M
|
$1.32 M
|
$5.94 M
|
$4.93 M
|
$1.45 M
|
$263.92 K
|
$217.60 K
|
$182.28 K
|
$256.22 K
|
| Gross Profit |
$604.54 M
|
$360.31 K
|
$109.14 K
|
$5.12 M
|
$4.69 M
|
$877.17 K
|
$24.38 K
|
$59.45 K
|
$130.93 K
|
$170.78 K
|
| Gross Profit Ratio |
0.3
|
0.21
|
0.08
|
0.46
|
0.49
|
0.38
|
0.08
|
0.21
|
0.42
|
0.4
|
| Research and Development Expenses |
$592.57 M
|
$1.26 M
|
$1.41 M
|
$120.04 K
|
$193.37 K
|
$338.87 K
|
$195.04 K
|
$234.49 K
|
$267.06 K
|
$424.43 K
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.34 B
|
$4.76 M
|
$5.06 M
|
$3.32 M
|
$2.56 M
|
$2.57 M
|
$2.30 M
|
$1.30 M
|
$1.14 M
|
$1.98 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$3.94 B
|
$6.02 M
|
$6.47 M
|
$3.44 M
|
$2.75 M
|
$2.91 M
|
$2.49 M
|
$1.53 M
|
$1.41 M
|
$2.40 M
|
| Cost And Expenses |
$5.38 B
|
$7.41 M
|
$7.79 M
|
$9.38 M
|
$7.68 M
|
$4.36 M
|
$2.76 M
|
$1.75 M
|
$1.59 M
|
$2.66 M
|
| Interest Income |
$21.40 M
|
$79.47 K
|
$209.15 K
|
$68.42 K
|
$2.99 K
|
$15.55 K
|
$58.85 K
|
$11.19 K
|
$785.00
|
$4.91 K
|
| Interest Expense |
-$156.21 M
|
$12.65 K
|
$27.92 K
|
$15.69 K
|
$12.93 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.47 K
|
| Depreciation & Amortization |
$0.00
|
$135.76 K
|
$167.29 K
|
$288.69 K
|
$123.66 K
|
$65.13 K
|
$43.91 K
|
$30.76 K
|
$10.61 K
|
$25.30 K
|
| EBITDA |
-$3.33 B |
-$5.53 M |
-$6.19 M |
$1.97 M |
$2.07 M |
-$1.97 M |
-$2.42 M |
-$1.44 M |
-$1.27 M |
-$2.21 M |
| EBITDA Ratio |
-1.63
|
-3.15
|
-4.35
|
0.18
|
0.21
|
-0.84
|
-8.41
|
-5.21
|
-4.05
|
-5.17
|
| Operating Income Ratio |
-1.63
|
-3.23
|
-4.47
|
0.15
|
0.2
|
-0.87
|
-8.56
|
-5.32
|
-4.08
|
-5.22
|
| Total Other Income/Expenses Net |
-$407.95 M
|
$109.39 K
|
-$29.85 K
|
$508.01 K
|
$129.68 K
|
$8.65 K
|
$41.95 K
|
$11.11 K
|
$15.00 K
|
$2.75 K
|
| Income Before Tax |
-$3.74 B
|
-$5.55 M
|
-$6.39 M
|
$2.19 M
|
$2.07 M
|
-$2.02 M
|
-$2.43 M
|
-$1.46 M
|
-$1.26 M
|
-$2.23 M
|
| Income Before Tax Ratio |
-1.83
|
-3.17
|
-4.49
|
0.2
|
0.22
|
-0.87
|
-8.41
|
-5.28
|
-4.04
|
-5.22
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$3.74 B
|
-$5.55 M
|
-$6.39 M
|
$2.19 M
|
$2.07 M
|
-$2.02 M
|
-$2.43 M
|
-$1.46 M
|
-$1.26 M
|
-$2.23 M
|
| Net Income Ratio |
-1.83
|
-3.17
|
-4.49
|
0.2
|
0.22
|
-0.87
|
-8.41
|
-5.28
|
-4.04
|
-5.22
|
| EPS |
0 |
-1.16 |
-1.34 |
0.46 |
0.44 |
-0.43 |
-0.51 |
-0.31 |
-0.27 |
-0.48 |
| EPS Diluted |
0 |
-1.16 |
-1.34 |
0.23 |
0.22 |
-0.43 |
-0.51 |
-0.31 |
-0.27 |
-0.48 |
| Weighted Average Shares Out |
$0.00
|
$4.80 M
|
$4.77 M
|
$4.76 M
|
$4.73 M
|
$4.73 M
|
$4.73 M
|
$4.71 M
|
$4.63 M
|
$4.60 M
|
| Weighted Average Shares Out Diluted |
$0.00
|
$4.80 M
|
$4.77 M
|
$9.49 M
|
$9.46 M
|
$4.73 M
|
$4.73 M
|
$4.71 M
|
$4.63 M
|
$4.60 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
